Product Name: Pegcetacoplan
CAS No: 2019171-69-6
Purity: 95%
Molar Mass: 43520.1
Chemical Formula: C1970H3848N50O947S
Synonyms: APL-2
Storage: Store at -20℃
Target: complement inhibitor
Application: Pegcetacoplan (CAS: 2019171-69-6) is a pegylated small molecule inhibitor of complement component 3 (C3) used in the treatment of various complement-mediated disorders. It functions by selectively binding to C3 and inhibiting its cleavage into biologically active fragments, thereby blocking the activation of the complement cascade. Pegcetacoplan is particularly effective in conditions characterized by dysregulated complement activation, such as paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases. In pharmaceutical chemistry, pegcetacoplan’s targeted inhibition of C3 represents a significant advancement in the management of complement-related disorders, offering a specific and effective therapeutic approach to modulate the dysregulated immune response underlying these conditions. Its application underscores its importance in improving outcomes and quality of life for patients with PNH and other complement-mediated diseases. Additionally, ongoing research explores pegcetacoplan’s potential in other complement-driven disorders and its role in combination therapies, highlighting its versatility in immune-mediated therapeutics.
Reference:
Hoy, S. M. (2021). Pegcetacoplan: first approval. Drugs, 81, 1423-1430.
